PURPOSE: Tyrosinase-related protein-1 (TYRP1) is a transmembrane glycoprotein that is specifically expressed in melanocytes and melanoma cells. Preclinical data suggest that mAbs targeting TYRP1 confer antimelanoma activity. IMC-20D7S is a recombinant human IgG1 mAb targeting TYRP1. Here, we report the first-in-human phase I/Ib trial of IMC-20D7S. EXPERIMENTAL DESIGN: The primary objective of this study was to establish the safety profile and the MTD of IMC-20D7S. Patients with advanced melanoma who progressed after or during at least one line of treatment or for whom standard therapy was not indicated enrolled in this standard 3 + 3 dose-escalation, open-label study. IMC-20D7S was administered intravenously every 2 or 3 weeks. RESULTS: Twenty-seven patients were enrolled. The most common adverse events were fatigue and constipation experienced by nine (33%) and eight (30%) patients, respectively. There were no serious adverse events related to treatment, no discontinuations of treatment due to adverse events, and no treatment-related deaths. Given the absence of dose-limiting toxicities, an MTD was not defined, but a provisional MTD was established at the 20 mg/kg every 2-week dose based on serum concentration and safety data. One patient experienced a complete response. A disease control rate, defined as stable disease or better, of 41% was observed. CONCLUSION: IMC-20D7S is well tolerated among patients with advanced melanoma with evidence of antitumor activity. Further investigation of this agent as monotherapy in selected patients or as part of combination regimens is warranted. Clin Cancer Res; 22(21); 5204-10. ©2016 AACR.

Department of Medical Oncology Dana Farber Cancer Institute Boston Massachusetts

Division of Medical Oncology Norris Comprehensive Cancer Center Keck School of Medicine University of Southern California Los Angeles California

Eli Lilly and Company New York New York

Kyowa Hakko Kirin Pharma Inc Princeton New Jersey

Massachusetts General Hospital Boston Massachusetts

Memorial Sloan Kettering Cancer Center Ludwig Center for Cancer Immunotherapy New York New York

Merck Research Laboratories North Wales Pennsylvania

Sotio Prague Czech Republic

Zobrazit více v PubMed

American Cancer Society. Cancer Facts & Figures 2014. Atlanta: American Cancer Society; 2014.

Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. [cited 2015 Apr 21];N Engl J Med [Internet] 2015 150419053123009. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25891173. PubMed

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. [cited 2015 Jun 2];N Engl J Med [Internet] 2015 Available from: http://www.ncbi.nlm.nih.gov/pubmed/26027431. PubMed PMC

Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. [cited 2015 Jun 7];Lancet [Internet] 2015 386:444–451. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26037941. PubMed

Larkin J, Ascierto PA, Dréno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. [cited 2015 Aug 20];N Engl J Med [Internet] 2014 371:1867–1876. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25265494. PubMed

Ghanem G, Fabrice J. Tyrosinase related protein 1 (TYRP1/gp75) in human cutaneous melanoma. [cited 2015 Aug 21];Mol Oncol [Internet] 2011 5:150–155. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21324755. PubMed PMC

Takechi Y, Hara I, Naftzger C, Xu Y, Houghton AN. A melanosomal membrane protein is a cell surface target for melanoma therapy. [cited 2015 Aug 26];Clin Cancer Res [Internet] 1996 2:1837–1842. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9816138. PubMed

Tai T, Eisinger M, Ogata S, Lloyd KO. Glycoproteins as differentiation markers in human malignant melanoma and melanocytes. [cited 2015 Aug 26];Cancer Res [Internet] 1983 43:2773–2779. Available from: http://www.ncbi.nlm.nih.gov/pubmed/6850592. PubMed

Journe F, Id Boufker H, Van Kempen L, Galibert M-D, Wiedig M, Salès F, et al. TYRP1 mRNA expression in melanoma metastases correlates with clinical outcome. [cited 2015 Aug 21];Br J Cancer [Internet] 2011 105:1726–1732. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3242608&tool=pmcentrez&rendertype=abstract. PubMed PMC

Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science [Internet] 2013;341:1192–1198. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24031011. PubMed

Boross P, Leusen JHW. Mechanisms of action of CD20 antibodies. [cited 2015 Aug 20];Am J Cancer Res [Internet] 2012 2:676–690. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3512181&tool=pmcentrez&rendertype=abstract. PubMed PMC

Welt S, Mattes MJ, Grando R, Thomson TM, Leonard RW, Zanzonico PB, et al. Monoclonal antibody to an intracellular antigen images human melanoma transplants in nu/nu mice. [cited 2015 Aug 26];Proc Natl Acad Sci U S A [Internet] 1987 84:4200–4204. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=305052&tool=pmcentrez&rendertype=abstract. PubMed PMC

Hara I, Takechi Y, Houghton AN. Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. [cited 2015 Aug 26];J Exp Med [Internet] 1995 182:1609–1614. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2192219&tool=pmcentrez&rendertype=abstract. PubMed PMC

Clynes R, Takechi Y, Moroi Y, Houghton a, Ravetch JV. Fc receptors are required in passive and active immunity to melanoma. [cited 2015 Aug 26];Proc Natl Acad Sci U S A [Internet] 1998 95:652–656. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=18475&tool=pmcentrez&rendertype=abstract. PubMed PMC

Liu G, Tu D, Lewis M, Cheng D, Sullivan LA, Chen Z, et al. Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer. [cited 2016 May 15];Clin Cancer Res [Internet] 2016 22:2435–2444. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27179112. PubMed

Bekaii-Saab TS, Roda JM, Guenterberg KD, Ramaswamy B, Young DC, Ferketich AK, et al. A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. [cited 2016 Jun 23];Mol Cancer Ther [Internet] 2009 8:2983–2991. NIH Public Access; Available from: http://www.ncbi.nlm.nih.gov/pubmed/19887543. PubMed PMC

Srivastava RM, Lee SC, Andrade Filho Pa, Lord Ca, Jie HB, Davidson HC, et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res. 2013;19:1858–1872. PubMed PMC

Derer S, Glorius P, Schlaeth M, Lohse S, Klausz K, Muchhal U, et al. Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity. [cited 2015 Aug 27];MAbs [Internet] 6:409–421. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3984330&tool=pmcentrez&rendertype=abstract. PubMed PMC

Petricevic B, Laengle J, Singer J, Sachet M, Fazekas J, Steger G, et al. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients. [cited 2015 Jul 31];J Transl Med [Internet] 2013 11:307. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4029549&tool=pmcentrez&rendertype=abstract. PubMed PMC

DiLillo DJ, Ravetch JV. Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect. [cited 2015 May 12];Cell [Internet] 2015 Available from: http://www.ncbi.nlm.nih.gov/pubmed/25976835. PubMed PMC

Hilchey SP, Hyrien O, Mosmann TR, Livingstone AM, Friedberg JW, Young F, et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: Support for a “vaccinal effect” of rituximab. Blood. 2009;113:3809–3812. PubMed PMC

Abès R, Gélizé E, Fridman WH, Teillaud JL. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood. 2010;116:926–934. PubMed